MAP1A (Microtubule Associated Protein 1A)

In summary, this study elucidates the biological functions of DDX60 in CRC and provides novel experimental evidence supporting its potential as a therapeutic biomarker.

Our discovery of Utt-B, a phytosaponin that exhibits remarkable anti-HCC potential and is a United States FDA-designated orphan drug against HCC, has gained global recognition. The present study reveals Utt-B as a propitious candidate drug against MASH and MASH-induced HCC in a high-fat diet murine model and streptozotocin-induced steatohepatitis-derived HCC animal model, respectively.

Our findings provide novel insights into OC molecular mechanisms and highlight promising therapeutic targets, establishing a foundation for future research and clinical applications.

Our findings demonstrate potential driver genes and mutational hotspots associated with CRC patient, characterizing the mutational landscape related to clinical characteristics. Significantly advancing our understanding of CRC's heterogeneous nature, this study lays a solid foundation for devising more efficacious management strategies.

These findings highlight UB as a promising dietary-derived metabolite for lung cancer prevention and therapy. Our study suggests that UB exerts its anti-tumor effects in part through the induction of autophagy associated with the AMPK/mTOR pathway and concomitant modulation of the gut microbiota, emphasizing the critical role of food-gut interactions in cancer management.

UNAs are partly accounted for by a repertoire of diverse mostly intracellular synaptic antigens. Their characterization is expedited by protein arrays and PhIPSeq. Further individual studies are needed to assess them as disease biomarkers.

Genomic alterations and reduced TIL density underpin trastuzumab resistance. The novel TRAG signature and integrated prognostic model enhance risk stratification and may guide personalized adjuvant therapy in early-stage HER2+ BC.

Groups included control (C57BL/6), model (normal saline), low/medium/high-dose FFQD, and western medicine (atorvastatin + metformin)...FFQD may improve insulin resistance, regulate glucose and lipid metabolism, inhibit excessive autophagy, induce macrophage polarization, resist inflammation and oxidative stress, inhibit atherosclerosis, and ultimately improve DMD by activating the RAGE/PI3K/AKT/mTOR and RAP1/PI3K/AKT/FOX01 pathways. Therefore, FFQD may be a promising candidate for DMD treatment.

Experimental validation via reverse transcription-quantitative polymerase chain reaction (RT-qPCR) confirmed that all six prognostic genes were significantly downregulated in BLCA clinical samples collected for this study. Overall, the study highlights six novel prognostic biomarkers and presents a robust predictive model, providing new insights into BLCA prognosis.

In conclusion, NR4A3 suppresses BC progression by promoting autophagy via the PI3K/AKT/mTOR pathway. Targeting NR4A3-mediated autophagy may provide a novel therapeutic strategy for BC.

Our study provides compelling evidence that curcumin inhibits the proliferation and migration of cisplatin-resistant HeLa cells by promoting autophagy through the downregulation of ERO1α and inhibition of the PI3K/AKT pathway.

Although pro-DCD or its PEGylation derivatives failed to directly kill bacteria across a wide range of concentrations, they were able to activate microtubule-associated protein 1A/1B-light chain 3 (LC3), a marker of autophagy and phagosome maturation in LC3-associated bacterial phagocytosis. Our findings suggest that pro-DCD-derived agents hold promise as potential therapies for clinical sepsis.